Phase 2 study of T138067-sodium in patients with malignant glioma
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group Sarah Kirby 2 , Stan Z
Phase 2 study of T138067-sodium in patients with malignant glioma
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group Sarah Kirby 2 , Stan Z
Clinical Trial: T138067 Sodium in Treating Patients With Advanced
Leukemia, Adult Acute ; Leukemia, Adult Chronic ; Leukemia, Childhood ; Lymphoma ; Multiple Myeloma. Study Type: Interventional. Study Design: Treatment Official Title: Phase I Study of T138067 Sodium
ICARE - Stage IV Prostate Cancer Clinical Trials
99 : Phase I Study of T138067 Sodium in Patients with Advanced Refractory Cancer : MSKCC-98004 . NCI-G98-1443 TULA-T9801 : 100 : Phase I Study of Temozolomide in Patients with
ICARE - Clinical Trials for Stage IV NHL
41 : Phase I Study of T138067 Sodium in Patients with Advanced Refractory Cancer : MSKCC-98004 . NCI-G98-1443 . TULA-T9801 42 : Phase I Study of the Biologic and Clinical Effects of
Sheet2
8 "A Phase I/II open Label Study of T138067- sodium Patients With Advanced Surgically Unresectable Hepatocellalur Carcinoma" 9 "A Phase III Randomized Controlled Study Comparing the Survival
NCIC CTG Group Publications - Journals
Phase 2 study of T138067-sodium in patients with malignant glioma: Trial of the National Cancer Institute of Canada Clinical Trials Group. Neuro-Oncology 7: 183-8, 2005
NCIC CTG Group Publications - Abstracts
A phase II study of T138067-sodium in patients with malignant glioma. A trial of the NCI Canada Clinical Trials Group. Presented: 7th Annual Meeting Society for Neuro-Oncology, 2002
www3.ccc.uab.edu
A Phase II/III, Multicenter, Randomized, Controlled, Open-Label Study of Intravenous T138067-Sodium versus Intravenous Doxorubicin in Subjects with Chemotherapy-Naïve, Unresectable Hepatocellular
Komen Foundation | Awarded Grants
Study Section: Treatment. Scientific Abstract: Survivin, a novel member of the recently discovered that treatment of MCF-7 breast cancer cells with T138067, a novel antitumor drug currently in Phase II

Phase 2 study of T138067-sodium in patients with malignant glioma
We studied the activity of T138067-sodium in patients with malignant gliomas. T138067-sodium is a un
ASCO - A phase II study of T138067-sodium in prior taxane-treated
The American Society of Clinical Oncology (ASCO) is the world's leading professional organization representing physicians who treat people with cancer.
Sheet2
8, "A Phase I/II open Label Study of T138067- sodium Patients With Advanced Surgically Unresectable Hepatocellalur Carcinoma"
Clinical Trial: T138067 Sodium in Treating Patients With Advanced
PURPOSE: Phase I trial to study the effectiveness of T138067 sodium in treating Official Title: Phase I Study of T138067 Sodium in Patients With
UCSF - UCSF Comprehensive Cancer Center - People - Thierry Marie
A Phase II Study of T138067-Sodium in Prior Taxane-Treated Patients (Pts) with Locally Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).

Clinical Trial: T138067 Sodium in Treating Patien With Advanced
PURPOSE: Phase I trial to study the effectiveness of T138067 sodium in treating Official Title: Phase I Study of T138067 Sodium in Patien With
Clinical Trial: T138067 Versus Doxorubicin in Chemotherapy-Naive
A total of 750 subjec will be enrolled in this study. Drug: T138067 inenous Drug: doxorubicin inenous, Phase II · Phase III
UCSF UCSF Comprehensive Cancer Center People Thierry Marie
A Phase II Study of T138067-Sodium in Prior Taxane-Treated Patien (P) with Locally Advanced or Metastatic Non Small-Cell Lung Cancer (NSCLC).
Systemic Therapy of Advanced Hepatocellular Carcinoma: How Hopeful
A phase II study of T138067-sodium in patien (p) with unresectable hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol 2002;20:572a.
DOI: 10.1634/theoncologist.11-7-790 2006;11;790-800 Oncologist
A phase II study of T138067-sodium. in patien (p) with unresectable hepatocellular carcinoma (HCC). Proc. AmSoc ClinOncol 2002;20:572a.
Recombinant leukocyte interferon, doxorubicin, and 5FUDR in
AP (2002) A phase II study of T138067- sodium in patien. (p) with unresectable hepatocellular carcinoma. Proc Am Soc. Clin Onc 21:144a
Phase I and Pharmacokinetic Study of Tasidotin Hydrochloride
the investigational antimicrotubule agent T138067 before treatment with tasidotin Phase I study with a weekly 1 h infusion of paaxel in heavily
CURRICULUM VITAE
Donehower R.C., Schwartz G., Wolff A.C., Olivo N., Burks K.L., Wright M., Walling J., Rowinsky, E.K A phase I pharmacokinetic study of T138067